High impact information on MAFOSFAMIDE LYSINE

• When using HL-60 cells as the target, the antileukemic activity of VP-16 was lower than of Asta-Z 7654 [1].
• In the present study we evaluated the effect of etoposide (VP-16-213) compared to mafosfamide-cyclohexylamine (Asta-Z 7654) on normal granulocyte-macrophage colony-forming unit (GM-CFU) growth, T-cell response to mitogens, and a clonogenic promyelocytic cell line (HL-60) [1].
• In 23 cases, bone marrow cells had previously been treated in vitro with Asta-Z 7654 (n = 7) or with monoclonal antibodies plus complement (n = 16) [2].
• In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213) [3].
• The immunohematopoietic reconstitution of mice lethally irradiated (TBI) and reconstituted with syngeneic bone marrow cells untreated or treated with mafosfamide (ASTA Z 7654) [TBI + SBMT or TBI + SBMT-Maf mice, respectively] was examined [4].

Biological context of MAFOSFAMIDE LYSINE

• The kinetics of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (ASTA Z 7654) [4].

Anatomical context of MAFOSFAMIDE LYSINE

• Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654) [5].
• The results demonstrated that LND increased the efficacy of anthracycline derivatives (Adriamycin, Mitoxantrone) both on the tumor cell line and on the leukemic blast progenitors, while VP-16 or ASTA-Z 7654 was not affected by the same substance [6].

Analytical, diagnostic and therapeutic context of MAFOSFAMIDE LYSINE

• Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation [7].

References